How to Monitor Insomnia Response With ISI After Mirtazapine
How should clinicians track short-term insomnia response after starting ultra-low-dose mirtazapine?
When ultra-low-dose mirtazapine is used for chronic insomnia, clinicians need a practical way to determine whether the patient is meaningfully improving. This guide applies the article's measurement approach and response thresholds using the Insomnia Severity Index over the first 1 to 3 months.
-
Measure baseline insomnia severity with the ISI
Before starting treatment, collect a baseline Insomnia Severity Index score. In the study, ISI was the validated instrument used to quantify perceived insomnia severity and served as the primary outcome measure.
-
Repeat the ISI at 1 to 3 months
Reassess insomnia severity 1 to 3 months after initiating mirtazapine 3.75 mg. This was the article's follow-up window for evaluating short-term efficacy.
-
Define clinically significant improvement by change from baseline
Interpret response as clinically significant when the ISI score is more than 7 points lower than baseline. This was the study's prespecified threshold for meaningful improvement.
-
Identify recovery using the absolute ISI score
Classify recovery when the follow-up ISI score is 7 or lower. The article used this cutoff to determine which patients had reached recovery.
-
Compare the patient's course with the study's short-term outcomes
Use the article's observed results to contextualize response over the first 1 to 3 months. Across all 53 veterans evaluated, 47% achieved a clinically significant ISI reduction and 32% reached recovery; among treatment completers with valid follow-up data, mean ISI changed from 20.4 to 8.9, with a mean decrease of 11.3.
Clinical Considerations
- The 1-to-3-month follow-up ISI results were based on patients who completed treatment and had a valid ISI score.
- Because 17 of 53 veterans did not complete treatment, observed improvement rates may not reflect all patients who start therapy.
- The study assessed perceived insomnia severity with ISI and did not establish long-term response beyond 3 months.
- The absence of a control group limits interpretation of how much ISI improvement was specifically attributable to mirtazapine.
Bottom Line
Track mirtazapine response with ISI at baseline and again at 1 to 3 months, using a drop of more than 7 points for clinically significant improvement and a score of 7 or lower for recovery.
